Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CYP2D6 polymorphism in patients with eating disorders

The Pharmacogenomics Journal volume 12, pages 173–175 (2012)Cite this article

Subjects

Abstract

CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571–574.

    Article  Google Scholar 

  2. LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM . Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004; 59: 869–873.

    Article  CAS  Google Scholar 

  3. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM . Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 321–336.

    Article  Google Scholar 

  4. LLerena A, Dorado P, Peñas-Lledó EM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17–28.

    Article  CAS  Google Scholar 

  5. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ . Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173–181.

    Article  CAS  Google Scholar 

  6. Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15: 579–587.

    Article  CAS  Google Scholar 

  7. Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339–347.

    Article  CAS  Google Scholar 

  8. Miksys SL, Tyndale RF . Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27: 406–415.

    PubMed  PubMed Central  Google Scholar 

  9. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L . Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23–28.

    Article  CAS  Google Scholar 

  10. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A . Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9: 833–840.

    Article  Google Scholar 

  11. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A . Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009; 10: 1111–1120.

    Article  Google Scholar 

  12. Peñas-Lledó EM, Dorado P, LLerena A . Pharmacogenomics and personality: role of CYP2D6 and implication for psychopathology. In: Schwab M, Kaschka W, Spina E (eds). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 2. Karger Publishers: Basel, 2010, pp 30–45.

    Chapter  Google Scholar 

  13. Zackrisson AL, Lindblom B, Ahlner J . High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354–359. (Published online 11 November 2009).

    Article  CAS  Google Scholar 

  14. Kawanishi C, Lundgren S, Agren H, Bertilsson L . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803–807.

    Article  CAS  Google Scholar 

  15. Josefsson A, Sydsjö G, Berg G, Dahl ML, Wadelius M, Nordin C . CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum. Nord J Psychiatry 2004; 58: 61–64.

    Article  Google Scholar 

  16. Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA et al. Symptom profile of major depressive disorder in females with eating disorders. Aust N Z J Psychiatry 2007; 41: 24–31.

    Article  Google Scholar 

  17. Peñas-Lledó E, Fernández-Aranda F, Jiménez-Murcia S, Granero R, Penelo E, Soto A et al. Subtyping eating disordered patients along drive for thinness and depression. Behav Res Ther 2009; 47: 513–519.

    Article  Google Scholar 

  18. Ribasés M, Fernández-Aranda F, Gratacòs M, Mercader JM, Casasnovas C, Núñez A et al. Contribution of the serotoninergic system to anxious and depressive traits that may be partially responsible for the phenotypical variability of bulimia nervosa. J Psychiatr Res 2008; 42: 50–57.

    Article  Google Scholar 

  19. LLerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A . Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007; 7: 408–410.

    Article  CAS  Google Scholar 

  20. Bacaltchuk J, Hay P . Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003. Issue no 4. Article no. CD003391.

Download references

Acknowledgements

This study was partially supported by grants from Instituto de Salud Carlos III (ISCIII)-FIS and European Union-FEDER PI081714 and CP06/00030 (Pedro Dorado). CIBER is an initiative of ISCIII (Spain). The study was coordinated within the network Red Iberoamericana de Farmacogenética y Farmacogenómica (CYTED206RT0290 www.ribef.org). The collaboration of Beatriz Grillo and Inés López in the genetic analysis and of Jesús Cobaleda in the evaluation of primary health-care attendants is gratefully acknowledged.

Author information

Authors and Affiliations

  1. CICAB Clinical Research Center, Extremadura University Hospital Medical School, Fundesalud and CIBERSAM, Badajoz, Spain

    E M Peñas-LLedó, P Dorado & A LLerena

  2. Department of Psychiatry, University Hospital of Bellvitge-IDIBELL and Ciber Fisiopatologia Obesidad y Nutrición (CIBEROBN), Instituto Salud Carlos III, Barcelona, Spain

    Z Agüera & F Fernández-Aranda

  3. Genes and Disease Program, Center for Genomic Regulation (CRG-UPF) and CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

    M Gratacós & X Estivill

  4. Department of Clinical Sciences, University of Barcelona, Spain

    F Fernández-Aranda

Authors
  1. E M Peñas-LLedó
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Agüera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Gratacós
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X Estivill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Fernández-Aranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A LLerena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to F Fernández-Aranda or A LLerena.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peñas-LLedó, E., Dorado, P., Agüera, Z. et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 12, 173–175 (2012). https://doi.org/10.1038/tpj.2010.78

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.78

Keywords

This article is cited by

Search

Advanced search

Quick links